Ob/Gyn Medical News about postmenopausal osteoporosis; increased risk of fracture; bazedoxifene

Become a Member Today!
Register

Most Viewed Abstracts

1. Report Shows Shift in Starting Salaries for Physicians

2. Taxane-based combinations as adjuvant chemotherapy of early breast cancer: a meta-analysis of randomized trials

3. Gene expression signatures, clinicopathological features, and individualized therapy in breast cancer

4. 2008 Exclusive Survey—Earnings: Good news for primary care income

5. Paclitaxel plus bevacizumab versus paclitaxel alone for metastatic breast cancer

Your Article Summary

See Latest Articles

(Click the title below to leave the MDLinx Network and go to the Journal's Website)

Treating postmenopausal osteoporosis in women at increased risk of fracture – critical appraisal of bazedoxifene: a review
International Journal of Women's Health, 08/18/09

Vestergaard P et al. – Several categories of drugs to treat osteoporosis exist in the form of bisphosphonates, strontium, parathyroid hormone, and selective estrogen receptor modulators (SERM). Bazedoxifene is a new member of the SERM group...The results indicate that bazedoxifene may be effective in preventing vertebral fractures in postmenopausal women with osteoporosis.

Methods

Systematic search of Pubmed, Embase, and Web of Science on June 19, 2009, using the term ‘bazedoxifene’

Results

One 3–year randomized double–blind placebo controlled trial with fractures as end–point was identified in which 7492 postmenopausal women aged 55 to 85 years were randomly allocated to 1) bazedoxifene (20 or 40 mg/day); 2) raloxifene (60 mg/day); or 3) placebo. Around two thirds of the included patients completed the trial.
The risk of vertebral fractures decreased with both 20 and 40 mg of bazedoxifene per day compared to placebo.
There was no reduction in non–vertebral fractures.
In post–hoc analyses, high risk subgroup of women with a priori high risk of fractures has shown a decrease in non–vertebral fracture risk with the 20 mg dose of bazedoxifene .

<< Previous
Arzoxifene: the evidence for its development in the management of...

Next >>
Comparison of transabdominal versus transvaginal ultrasound to...